Dihydromitragynine in the wild — receptor profile, half-life, and what makes it harder to quit than 7-OH.

Risks

Treat it as opioid-class — dependence, tolerance, withdrawal, and respiratory depression risk apply.
Community withdrawal reports look like classical opioid withdrawal, heavier and longer than 7-OH withdrawal because of the half-life.
Big harm-reduction note: products labeled “DHM” have been found containing 7-OH and other unlabeled compounds. Some vendor labels actually disclose this in the fine print. What’s on the label is not necessarily what’s in the bottle.
Naloxone reverses overdose.
Mixing with other depressants raises overdose risk significantly.

Recovery context

Because the published literature is sparse, most of what’s known about MIT-A/DHM in real-world use comes from lived experience in spaces like this. Sharing what tapering looked like, what withdrawal timelines have been, and what helped or didn’t is genuinely useful — both for people here and for the broader picture of what these compounds do in humans.

MIT-A / DHM (Dihydromitragynine)

What it is

MIT-A, sold and discussed as DHM (dihydromitragynine), is a semi-synthetic compound — the 1,2-dihydro reduction product of mitragynine itself, not of 7-OH. It is not the same as MGM-15 (which is the dihydro form of 7-OH and is also sometimes called “DHM” in academic papers — naming in this space is genuinely a mess, so when in doubt, ask).

Where it came from

Appeared in the U.S. market in 2025 as part of the wave of mitragynine-derived semi-synthetics being sold in tablet, gummy, and chewable form alongside 7-OH products, often through the same retailers and smoke shops.

Pharmacology

Reducing the 1,2 double bond of mitragynine changes its receptor profile and pharmacokinetics. Public peer-reviewed pharmacology specifically on dihydromitragynine as a standalone compound is thin — most published kratom-analog research has focused on mitragynine, 7-OH, MP, and MGM-15. That alone is worth flagging: people are taking it in real-world doses faster than the literature is keeping up.

In terms of where it sits on the spectrum of compounds people in this community are dealing with: leaf kratom < concentrated mitragynine extracts < 7-OH < MIT-A/DHM < pseudoindoxyl < MGM-15. The semi-synthetics and isolates all behave more like classical opioids than they do like the leaf material.

Half-life — same problem as MGM-15

Like MGM-15, MIT-A is a 1,2-dihydro reduction product, and that structural change extends its duration of action well beyond 7-OH. Community reports and the limited available data put it in the long-acting category — significantly longer than 7-OH’s few-hour duration. Practical consequences:

Effects and receptor occupancy persist far longer than people expect coming from 7-OH.
Withdrawal onset is delayed — often 24+ hours after last dose rather than the same-day rebound 7-OH users are used to.
Redosing on a 7-OH schedule causes accumulation. People underestimate how much is on board.

Why Suboxone is tricky with MIT-A — same logic as MGM-15

The same two issues that complicate Suboxone induction off MGM-15 apply here:

1. Precipitated withdrawal risk runs longer than the standard 12–24 hour window. Standard induction guidance was built around shorter-acting opioids. With MIT-A’s longer half-life, that wait often isn’t enough — there’s still meaningful drug on your receptors when bupe goes in, bupe displaces it as a partial agonist, activation drops, and precipitated withdrawal hits. A longer washout (closer to 36–72 hours when feasible) tends to be safer.

2. Bupe may not fully “take the edge off” — and it’s not in your head.

Buprenorphine has a ceiling effect — its maximum MOR activation is lower than what a full agonist was delivering. You’re stepping down receptor activation, not replacing it.
The published delta-receptor profile of MIT-A/DHM specifically isn’t well-characterized yet, but mitragynine-scaffold dihydro derivatives broadly tend toward dual MOR/DOR activity. If MIT-A is hitting delta at all, bupe (which is a delta antagonist) won’t replace that contribution to mood, analgesia, and overall opioid tone.
Net effect that matches what people report: bupe covers a lot but leaves a persistent low-grade “off” feeling — restlessness, anhedonia, low mood — that takes weeks to settle. Many people end up needing a higher stabilizing dose than their initial induction dose.

If you’re planning this transition, a longer washout, a prescriber who actually understands kratom-derivative dependence, and openness to a higher stabilizing dose all tend to make it go better. Share what’s worked or hasn’t here — community knowledge is genuinely ahead of the published literature on this compound.